A Phase IV Clinical Trial to Compare the Efficacy and Safety of Metformin+Sodium-Glucose Cotransporter 2 Inhibitor(SGLT2-i)+Thiazolidinedione (TZD) in Patients With Type 2 Diabetes

ConditionType 2 Diabetes

Trial statusRecruiting

Trial phasePhase 4

Trial typeInterventional

Biological sexAll

Age19+

SponsorBoryung Pharmaceutical Co., Ltd

About this trial

This is a randomized, open-label, active-controlled, parallel, multicenter, phase IV clinical study evaluating the efficacy and safety of switching Metformin+SGLT2-i+DPP4-i to Metformin+SGLT2-i+TZD in patients with type 2 diabetes.

Eligibility criteria

Qualifiers

Has voluntarily agreed to participate in this clinical trial.

Adults over 19 years of age

Diagnosed with type 2 diabetes

Disqualifiers

Has severe renal and liver disorders

Has type 1 diabetes

Those who are participating or have participated in other clinical trials and administered their investigational products within 8 weeks before the screening date for this study

Those who are deemed ineligible to participate in the study by the investigator

Trial design

Treatments tested in this trial

Metformin
Dapagliflozin/Pioglitazone
Dapagliflozin/Sitagliptin

Treatment groups

204 Participants

are divided into 2 treatment groups

Sponsors and collaborators

Boryung Pharmaceutical Co., Ltd

Lead sponsor

Source ClinicalTrials.gov